Clinical trials

alnylam.png
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3…
Read more
ionis-logo.png
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data today from the…
Read more
Taking Your Next Steps: Life Following hATTR Amyloidosis Diagnosis
Being diagnosed with hATTR amyloidosis can be overwhelming, frightening and hard to process. You may be asking yourself - where should I go from here? We have…
Read more
Amyloidosis: About Clinical Trials
Doctors and scientists are always looking for better ways to care for patients with amyloidosis. To make scientific advances, doctors create research studies…
Read more
Subscribe to